What type of study is this?

Multi‐Institutional Study of ALK‐Positive Large B‐Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies

View Full Paper

Ask AI

Bookmark

Authors

Retrospective analysis shows poor survival outcomes in ALK-positive lymphoma, suggesting need for targeted therapies.

Median event-free survival was only 0.6 years, indicating limited success of recent treatments.
One-year overall survival rate was found to be 72%, while the five-year rate dropped to 42%, highlighting aggressive nature of the disease.
Twelve patients received ALK inhibitors, with alectinib yielding better responses than crizotinib, pointing to therapy effectiveness.
Advanced stage and high IPI scores were consistently associated with worse outcomes, emphasizing the need for better disease management.

Atallah‐Yunes et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark